"rationale","uuid:ID","versionIdentifier","instanceType","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","a7721e6f-740d-41a9-ae6a-f04f912b8d97","2","StudyVersion","StudyVersion_1"
